

PLD1 Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP12199a**Specification****PLD1 Antibody (N-term) Blocking peptide -
Product Information**Primary Accession [Q13393](#)**PLD1 Antibody (N-term) Blocking peptide -
Additional Information****Gene ID** 5337**Other Names**Phospholipase D1, PLD 1, hPLD1, Choline
phosphatase 1,
Phosphatidylcholine-hydrolyzing
phospholipase D1, PLD1**Format**Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.**Storage**Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.**Precautions**This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.**PLD1 Antibody (N-term) Blocking peptide -
Protein Information****Name** PLD1 ([HGNC:9067](#))**Function**Function as phospholipase selective for
phosphatidylcholine (PubMed:<a href="http
://www.uniprot.org/citations/8530346"
target="_blank">8530346,
PubMed:<a href="http://www.uniprot.org/ci
tations/9582313"
target="_blank">9582313). Implicated
as a critical step in numerous cellular**PLD1 Antibody (N-term) Blocking peptide -
Background**Phosphatidylcholine (PC)-specific
phospholipases D (PLDs;EC 3.1.4.4) catalyze
the hydrolysis of PC to produce
phosphatidic acid and choline. A range of
agonists acting through G-protein-coupled
receptors and receptor tyrosine kinases
stimulate this hydrolysis. PC-specific PLD
activity has been implicated in numerous
cellular pathways, including signal
transduction, membrane trafficking, and the
regulation of mitosis (Hammond et al.,
1995[PubMed 8530346]).**PLD1 Antibody (N-term) Blocking peptide -
References**Bailey, S.D., et al. Diabetes Care
33(10):2250-2253(2010) Rose, J.E., et al. Mol.
Med. 16 (7-8), 247-253 (2010) :Kang, D.W., et
al. Cancer Res. 70(10):4233-4242(2010) Yin, H.,
et al. J. Biol. Chem.
285(18):13580-13588(2010) Kang, D.W., et al.
PLoS ONE 5 (8), E12109 (2010) :

pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. May be involved in the regulation of perinuclear intravesicular membrane traffic (By similarity).

Cellular Location

Cytoplasm, perinuclear region
{ECO:0000250|UniProtKB:Q9Z280}.
Endoplasmic reticulum membrane
{ECO:0000250|UniProtKB:Q9Z280};
Lipid-anchor
{ECO:0000250|UniProtKB:Q9Z280};
Cytoplasmic side
{ECO:0000250|UniProtKB:Q9Z280}. Golgi
apparatus membrane
{ECO:0000250|UniProtKB:Q9Z280};
Lipid-anchor
{ECO:0000250|UniProtKB:Q9Z280};
Cytoplasmic side
{ECO:0000250|UniProtKB:Q9Z280}. Late
endosome membrane
{ECO:0000250|UniProtKB:Q9Z280};
Lipid-anchor
{ECO:0000250|UniProtKB:Q9Z280};
Cytoplasmic side
{ECO:0000250|UniProtKB:Q9Z280}

Tissue Location

Expressed abundantly in the pancreas and heart and at high levels in brain, placenta, spleen, uterus and small intestine

PLD1 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)